MT-1303 is an investigational drug.
There have been 12 clinical trials for MT-1303.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2013.
The most common disease conditions in clinical trials are Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, and Crohn Disease. The leading clinical trial sponsors are Mitsubishi Tanabe Pharma Corporation, Bausch Health Americas, Inc., and [disabled in preview].